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Abstract: Scientific knowledge on depression and anxiety in patients with rare diseases during
the COVID-19 pandemic is scarce; however, it is essential to perform comprehensive management
of these patients. The aim of this study was to research how the situation caused by the SARS-
CoV-2 pandemic has influenced the lives of patients with rare diseases regarding depression and
anxiety. This Spanish study considered a heterogeneous population sample of 86 patients with
confirmed diagnosis of different rare diseases. Participants took part in a cross-sectional online
study by completing specific questionnaires on the study topic. Depression was measured using the
Patient Health Questionnaire (PHQ-9), and the General Anxiety Disorder Scale (GAD-7) was used for
evaluating anxiety. Data collection through an online questionnaire allowed for a greater population
scope and therefore the inclusion patients of other nationalities in the study sample. Finally, as a
general result, this study found that, in the face of the pandemic, anxiety and depression remained
at a higher level in this group than in the general population, making these patients a vulnerable
population group.
Keywords: rare disease; depression; anxiety; COVID-19; SARS CoV-2; pandemic
1. Introduction
Rare diseases are conditions that are mainly characterized by their low prevalence in
the population [1]. They are also known as orphan diseases. In order to be considered a rare
disease, it must affect fewer than 1 in 2000 people [2]. There may be as many as 7000 rare
diseases, 80% of which are genetic. These diseases are clinically and phenotypically
very heterogeneous due to the variability of expression of the mutated gene that causes
them. Most of these diseases are chronic and progressive and normally have an important
negative impact on the quality of life of the affected patients [1].
In order to fully grasp the complexity of rare diseases, it is necessary to study in
depth the different clinical aspects that characterize them, the specific circumstances that
surround each disease, and the repercussions they have on patients, their families and their
environment, as well as the interactions between the previously mentioned elements [3].
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Due to the low number of cases and the specificity of each disease, it is often the case
that scientific knowledge, and therefore, the scientific literature on each disease is directly
proportional to the number of cases that have been described [4].
This fact has a negative impact on the diagnostic phase, making it hard to establish a
definitive diagnosis at early stages. Diagnostic delay [5] hinders clinical management of
the disease, leading to a situation of uncertainty and chaos that is harmful for the patient,
worsening the symptoms of their disease and increasing the likelihood of development of
mental disorders.
On 11 March 2020, the World Health Organization declared the infectious disease
caused by the coronavirus discovered in 2019, named COVID-19, a pandemic [6]. Since
then, many governments have imposed a series of measures that make isolation and social
distancing compulsory. Namely, in Spain [7], the country in which this study was carried
out, measures of home confinement were established, and all non-essential services were
prohibited, as was free, non-justified circulation. Schools were closed and the use of face
masks was made obligatory, as was a social distance of 2 m. These measures remained in
place from 14 March to the end of June 2020. Over time, we have seen how the government
applied or lifted impositions depending on the state of the COVID-19 pandemic throughout
the country. These measures have limited the access to primary medical care, and access to
mental health services and other types of support centers has been greatly disrupted.
This pandemic and the public health measures that were established can have serious
psychological repercussions on any person. Additionally, patients with rare diseases may
be at risk of suffering debilitating psychological symptoms as a direct consequence of
the progression of their own disease [3]. Additionally, the development of this pandemic
negatively impacts these patients, who have become a vulnerable population group with
regard to the issue at hand [8].
There are studies that report the psychological burden and the increase in mental
health symptoms in patients with rare diseases [8,9]. The increase in depressive and anxiety
syndromes in certain rare diseases is also known [10], but in general, scientific publications
on the psychopathology of rare diseases are scarce and, even more so, with regard to how
they may relate to the worldwide COVID-19 pandemic.
Depression and anxiety are frequent psychosocial symptoms in chronic diseases [11].
Depression is a frequent mental disorder that is characterized by persistent sadness and a
loss of interest in activities that are normally enjoyable, accompanied by an incapability
to carry out daily activities. Anxiety is an emotional response that arises in the face of
situations that the person perceives or interprets as menacing or dangerous [12].
As no curative treatment exists for most rare diseases [1], it is of interest to study
depression and anxiety as related symptoms in a specific context, such as that generated by
the COVID-19 pandemic, as the treatment of such symptoms would likely improve the
global quality of life of these patients.
The aim of this study was to research how the situation caused by the SARS-CoV-2
pandemic has influenced the lives of patients with rare diseases regarding depression
and anxiety.
2. Materials and Methods
This study was a cross-sectional online study. Due to the pandemic situation caused by
the coronavirus SARS-CoV-2, the whole study was carried out using online questionnaires.
This way, it was possible for the study to acquire an international perspective.
The study was approved by the Ethics Committee of the province of Granada. At
all times, the study was performed in accordance with the guidelines of the Helsinki
Declaration, amended by the 64th General Assembly of the AMM, in Fortaleza, Brazil, in
October 2013. Before completing the online questionnaire, participants were requested
to give their informed consent online, by means of a box on the form that had to be
intentionally ticked in order to continue with the questionnaire.
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2.1. Participants
Patients were recruited through rare disease patient associations. Information on the
study was distributed via mailing lists of rare disease patient associations. An information
leaflet with information on the study was attached and the email included a link to an
online form specifically designed for this study (see in Supplementary Materials).
A special email address was created for this study, through which patients interested
in taking part could contact the research team with any questions.
All patients diagnosed with a rare disease could take part in the study. Diseases with
a prevalence of 1 in 2000 people were considered rare diseases and included in the study. If
no information regarding prevalence was available, patients were included if their disease
is listed on the Orpha.net registry of rare diseases [2].
The minimum age for participation in the study was 18 years of age, with no upper
limit. Patients with an unclear diagnosis, with a disease not considered a rare disease, or
patients who said that the diagnosis was not given by a doctor were excluded.
The patients who answered “Yes” to the question “Do you have a recent history of
symptoms of anxiety or depression in the months prior to the pandemic?” were excluded.
Extensive lists of symptoms of anxiety and depression were detailed in the question. The
symptoms of anxiety considered include psychological symptoms such as constant worry,
tiredness, irritability, and difficulty concentrating or sleeping problems, and physical
symptoms such as high heart rate, excessive sweating, muscle tension, shaking, dizziness,
and fainting. The symptoms of depression considered include irritable mood or an overall
low mood, sleep disorders (difficulty getting to sleep or excessive sleeping), changes in
appetite (often with associated weight changes), tiredness and low energy, feelings of
uselessness, self-hate and guilt, difficulty concentrating, slow or fast movements, feelings
of hopelessness or abandonment, repetitive thoughts regarding death or suicidal thinking,
and loss of pleasure in things that normally bring joy, including sexual activity.
The main researcher evaluated each questionnaire and those which did not fulfill the
three requirements (>18 years of age, confirmed diagnosis of a rare disease, and no recent
history of anxiety or depression) were excluded from the study.
Patients who failed to complete more than 85% of the questionnaire were also excluded.
2.2. Instruments
Depression was measured by the Patient Health Questionnaire (PHQ-9), an instrument
that scores 9 items that determine the level of severity of depressive symptoms [13–15].
Cut-off points of a total score of 5, 10, 15, and 20 represent mild, moderate, moderately
severe, and severe depression, respectively. A score of 10 or above is recommended by
the authors as a single cut-off point for major depression. The instrument has an excellent
internal reliability (α = 0.89), excellent test–retest reliability, and criterion and construct
validity [13].
Anxiety was evaluated by the General Anxiety Disorder scale (GAD-7) [15–17]. It
consists of seven questions that can be scored between 0 and 3; therefore, the minimum
and maximum scores possible are 0 and 21, respectively. To evaluate the results obtained
from the answered questionnaires, its authors suggest the following scores: 0–4, no anxiety
detected, 5–9, symptoms of mild anxiety detected, 10–14, symptoms of moderate anxi-
ety detected, and 15–21, symptoms of severe anxiety detected. It is recommended that
consultation with a healthcare professional should be sought if a score of 10 or above
is obtained.
Although it has the best operational characteristics for the detection of general anxiety
disorder, the instrument has proven to be useful in the detection of any other anxiety
disorder. The GAD–7 scale presents an excellent internal reliability (α = 0.92), good test–
retest reliability (ICC = 0.83) as well as criterion, construct, factorial, and procedural validity.
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2.3. Statistical Analyzsis
Mean and standard deviation were calculated for quantitative variables. Qualitative
variables were reported using frequencies.
The Kolmogorov–Smirnov test was applied to test for normal distribution of the
variables PHQ-9 score and GAD-7 score; of the two, the PHQ-9 could be considered normal
(p = 0.11), a skewness of 0.96 and a kurtosis of 0.33.
Student’s t–test was used to determine if there were differences between PHQ-9 and
GAD-7 scores according to whether the participant had been ill with COVID-19, had been
in close contact with a COVID-19 patient, had non-cohabiting family members or friends
who had been ill with COVID-19, had family members or close friends pass away due to
COVID-19, age, gender, education level, marital status, and body mass index.
The relationship between quantitative and categorical variables was measured using
the chi square test.
The relation between depression and anxiety was calculated applying Pearson’s
correlation coefficient.
3. Results
To assess the reliability of the questionnaires, Cronbach’s alpha coefficient was calcu-
lated. For the questionnaire that measures depression, the Patient Health Questionnaire
(PHQ-9), the Cronbach’s alpha coefficient was 0.90, whereas for the questionnaire that
measures anxiety, the General Anxiety Disorder scale (GAD-7), the coefficient was 0.94.
Overall, when all items were considered, the result was 0.95.
We analyzed a sample of 86 individuals, 76% of whom were female, and the mean
age of the study group was 42.74 years (SD = 13.43). The majority of those surveyed, 95%
(82 patients), lived in Spain, but there were also participants from Chile, Colombia, Holland
and Mexico. Nearly one third of the participants (33%) were not in paid employment,
either due to retirement or to recognition of permanent disability.
More than half of the participants, 57%, were married, followed by 33% who were
single. Most of the participants in the study (54%) had university level education, an
additional 9% had upper level professional training, and 14% had baccalaureate or middle
level training.
At the time of reporting, 89% did not use tobacco and only 13% drank alcohol regularly.
Six participants (7%) had been ill with COVID-19, all of whom were symptomatic,
and none required hospital admission. Regarding the symptoms experienced by the
participants who had COVID-19, the highest percentages were found for dry cough and
tiredness, followed by muscular pain and fever.
A minimum ten-day quarantine had to be completed by 21% (18 cases) of participants
due to having close contact with someone who had COVID-19, and 45% (39 cases) had
family members or close friends who had COVID-19 but did not have to be quarantined.
We found that 14% (12 cases) had lost at least one family member or close friend due to
COVID-19.
Analyzing the responses to the GAD-7 questionnaire, we observed no statistically
significant differences between sexes χ2(3, N = 86) = 0.21, p = 0.98, and found that 74% did
not have symptoms of anxiety or had mild symptoms (Table 1). Examining the answers
according to education level, we found that among those with severe anxiety, there was a
majority of individuals with university degrees (70%).
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Table 1. General Anxiety Disorder scale (GAD-7) questionnaire scores according to sex of the
studied population.
No Mild Moderate Severe Total
Women
n 20 28 9 8 65
% within sex 31 43 14 12 100
% within GAD-7 77 74 75 80 76
Men
n 6 10 3 2 21
% within sex 29 48 14 9 100
% within GAD-7 23 26 25 20 24
Total
n 26 38 12 10 86
% within sex 30 44 14 12 100
% within GAD-7 100 100 100 100 100
Regarding level of depression according to the score obtained from the PHQ-9 ques-
tionnaire, we found that 70% of the participants did not have symptoms of depression, or
such symptoms were mild or very mild. Only 16% (14 individuals) had moderately severe
or severe symptoms. The PHQ-9 scores were not associated to sex χ2(4, n = 86) = 2.24,
p = 0.69 (Table 2).
Table 2. Patient Health Questionnaire (PHQ-9) scores according to sex of the studied population.
No Mild ModerateModeratelySevere Severe Total
Women
n 22 21 10 7 5 65
% within sex 34 32 15 11 8 100
% within GAD-7 76 68 83 87 83 76
Men
n 7 10 2 1 1 21
% within sex 33 48 9 5 5 100
% within GAD-7 24 32 17 12 17 24
Total
n 29 31 12 8 6 86
% within sex 34 36 14 9 7 100
% within GAD-7 100 100 100 100 100 100
We found no statistically significant differences according to body mass index, nor
according to age in GAD-7 and PHQ-9 questionnaire scores.
There was a strong correlation r(86) = 0.75, p < 0.001, between the GAD-7 and PHQ-9
questionnaire scores, indicating that those who had the highest levels of anxiety were also
likely to have high levels of depression.
Table 3 shows the mean and standard deviations according to the answers to the
questions regarding COVID-19. Additionally, we used the t test to calculate the p value for
the comparison of the groups formed according to answer.
Table 3. Comparison of means and standard deviation according to answers by PHQ-9 and GAD-7 scores.
YES NO P
Have you been ill with COVID-19? PHQ–9 7.50 (5.28) 7.81 (6.46) 0.91
GAD–7 6.67 (3.39) 7.36 (5.57) 0.76
If you did not have COVID-19, have you been a close
contact of a COVID-19 patient?
PHQ–9 6.83 (6.18) 8.04 (6.42) 0.48
GAD–7 7.39 (5.49) 7.29 (5.46) 0.95
Have any of your non cohabiting family members or
close friends been ill with COVID-19?
PHQ–9 9.49 (6.30) 6.38 (6.12) 0.02
GAD–7 7.82 (5.66) 6.89 (5.26) 0.43
Have any of your family members or close friends
passed away due to COVID-19?
PHQ–9 10.33 (7.30) 7.38 (6.14) 0.14
GAD–7 9.58 (6.68) 6.95 (5.16) 0.12
As shown in Table 3, there were only differences in PHQ-9 scores amongst those
who had family members or close friends who had been ill with COVID-19 and those
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who did not. The highest score was found in those who had family members or friends
who had COVID-19. We found no differences in scores regarding sex, marital status or
education level.
4. Discussion
This research studied the impact on health and psychological wellbeing in patients
with rare diseases during the COVID-19 pandemic. More specifically, it focused on the
evaluation of the degree of anxiety and/or depression that patients with rare diseases
may have experienced during the pandemic. Patients with rare diseases are patients with
high requirements of healthcare; however, throughout the pandemic, access to healthcare
services has been limited and, in many cases, non-existent [18].
We have not found specific studies evaluating depression and anxiety in patients with
rare diseases during the pandemic. During our literature search, we only retrieved one
study, published prior to the pandemic, that focused on the same area of research as the
present study [19]. For this reason, we reviewed and used the literature on rare diseases in
general and specific rare diseases, and on chronic and rare diseases in which depression
and anxiety have been studied. We do not disregard the possibility of pursuing new future
lines of research to study all kinds of factors that affect anxiety and depression as well as
sexual disfunction in patients with rare diseases [15,20].
In order to evaluate the depression parameter, we used the validated PHQ-9 ques-
tionnaire, which has been proven to be precise in the evaluation of depressive states [21].
This questionnaire has been evaluated and has been proven to have good psychometric
properties. Therefore, it is considered an exact diagnostic tool for depressive states [22],
and it has been utilized by other authors to evaluate depression in patients with rare
diseases [4]. The contrast of results with those obtained in similar circumstances using the
same tools is therefore possible.
Our results indicate that 70% of the patients considered did not show signs of depression
or had some form of mild depression. Meanwhile, only 30% reported levels of moderately
severe depression. We also demonstrated that the highest percentages of moderate to severe
depression are found in female patients (34% of patients within same sex) compared to
male patients (20%). In the study on depression and anxiety in patients with rare diseases
published in 2019 [19], the results show that 42% of patients had symptoms of moderate or
severe depression compared to the 34% found in this study. However, in other studies that
focused on depression and anxiety during the pandemic [23,24] in the general population,
rates of depression were at 16% [24] and 19% [23], respectively. In a comparison of the
prevalence of depression in the general population during the pandemic and the prevalence
in patients with rare diseases, our study found that the prevalence of depression in patients
with rare diseases was nearly double that of the general population (30%).
For the study and evaluation of anxiety, we used the validated GAD-7 questionnaire.
This questionnaire has been used in previous studies with the same purpose [19,23]. The
data obtained in our study indicated that 26% of the patients considered had severe anxiety
compared to 74% who had mild anxiety or no symptoms of anxiety. In the previously
mentioned study in patients with rare diseases published prior to the pandemic [19],
researchers found that 23% of patients had anxiety. In studies carried out in the general
population during the pandemic, the results show percentages of moderate to severe
anxiety of 14% [22] and 29% [23], respectively.
In the systematic review carried out by Xiong et al. [25], where they analyzed 19 articles
that considered anxiety and depression in the general population during the pandemic,
rates of anxiety ranged from 6% to 19%. The results obtained in our study of patients with
rare diseases were higher, with the prevalence of depression ranging between 15% and
48%. These results for depression do not constitute a significant difference between the
general population group and the results of this study. In their study, Xiong et al. also
demonstrated that women had a higher rate of symptoms of depression than men [25],
as did other studies [23] on depression and anxiety in the general population. The age
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group most affected was those younger than 40 years of age, and in our study, we found
no relevance in the prevalence according to age.
On the other hand, there is a study on the impact of the pandemic in patients with rare
diseases that demonstrates that 66% of the patients included in the study found their health
care affected in some way during the pandemic. Around 46% of the study population
suffered direct effects on their health status and wellbeing. Additionally, 79% reported that
the pandemic had affected their mental health [25]. We did not find any articles including
situational parameters regarding COVID-19 (Have you been ill with COVID-19? Have you
been a close contact? etc.) such as those considered in this study in relation to anxiety and
depression in patients with rare diseases.
In this study, we demonstrated that those patients who had family members or friends
who were ill with COVID-19, even if they did not live together, had more symptoms of
anxiety and depression than those who had been ill themselves or had been a close contact
(p = 0.02). We did not find other published studies that relate depression and anxiety
parameters with the patient’s situation regarding COVID-19 in order to contrast this fact.
This study was performed using an online cross-sectional design, the method of
preference for other similar studies [19,26,27]. Among the weaknesses of cross-sectional
studies is the inability to determine the temporal relation between outcomes and risk
factors, so they are unable to establish if the exposure preceded the disease or vice versa.
Therefore, in our study, it is not possible to know if the symptoms of depression or anxiety
were present prior to the pandemic or arose due such circumstances.
Our sample included 86 patients, which constitutes a high “n” for the type of patients
considered. Other studies on patients with rare diseases have been performed in as few
as 15 patients [26]. Recruitment of this sample was carried out online, using online forms
for data collection, due to the state of emergency decreed by the national government.
This method has been used by other authors, including Ozamiz-Etxebarria [28], to collect
information during the pandemic period. The main advantages of this method, compared
to previous research methods, include privacy and timely management and access to the
results. This study included a patient support system for study participants, so patients
felt supported and were able to receive answers to their queries through an email account
specifically created for that purpose. We found no evidence of a similar channel being used
in other studies. Another interesting fact worth mentioning is the predominant female sex
in this study, as in others carried out among patients with rare diseases [19].
5. Conclusions
Patients with rare diseases are a population group who have high healthcare require-
ments, and health services have been deeply affected by the pandemic. Therefore, health
status and psychological wellbeing of these patients have also been affected.
As the results presented above suggest, levels of depression and anxiety may have
been influenced by the current pandemic state as levels of moderate or severe anxiety were
higher in patients with rare diseases than in those with other types of chronic diseases and
the general population, as it is found in 26% of the study population. Additionally, the
percentage of patients with moderate or severe depression (30%) among patients with rare
diseases during the pandemic nearly doubled the percentage of those affected in the general
population during the same period. However, comparing the results to those of a 2019
study in patients with rare diseases, the levels remained at similar levels prior to and during
the pandemic. This study found that symptoms such as anxiety and depression have a
higher prevalence among women than men. The uncertainty surrounding the pandemic
may increase anxiety and depression, as the patients with higher levels of symptoms are
those who had family members or close friends who had been ill or passed away due to
COVID-19, more so than those who were ill themselves. The study results indicate that
during the pandemic, anxiety/depression remained at a higher level in this group than in
the general population.
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Depression and anxiety in patients with rare diseases is an issue that needs further
research, as there are not many publications that consider rare diseases as a whole. There
are several articles on certain specific diseases, but none including patients with rare
diseases in general.
Supplementary Materials: Participants accessed and completed the questionnaires through the on-
line form link: https://docs.google.com/forms/d/e/1FAIpQLSdJ2woR6VTxl7LRt8-B1uTBrvHMaF0
_mChMMhxqsi2bYWiw9A/viewform?usp=sf_link.
Author Contributions: Conceptualization, J.C.-M., J.C.S.-G. and L.D.-R.; Methodology, R.R.-B.,
J.C.S.-G. and L.D.-R.; Validation, J.C.-M., A.E.M.-J., M.M.-T. and R.R.-B.; Formal Analysis, A.E.M.-J.
and J.C.S.-G.; Investigation, R.R.-B., J.C.S.-G., J.C.-M., M.M.-T., A.E.M.-J. and L.D.-R.; Resources, R.R.-
B. and M.M.-T.; Data Curation, A.E.M.-J. and J.C.S.-G.; Writing—Original Draft Preparation, J.C.-M.,
J.C.S.-G. and L.D.-R.; Writing—Review and Editing, J.C.-M., J.C.S.-G., L.D.-R., M.M.-T., A.E.M.-J.
and R.R.-B.; Visualization, R.R.-B. and L.D.-R.; Supervision, R.R.-B., J.C.S.-G. and L.D.-R.; Project
Administration, R.R.-B., J.C.S.-G. and L.D.-R. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki and approved by the Institutional Review Board of the province of Granada.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study. Online informed consent has been obtained from the patient(s) to publish this paper.
Acknowledgments: The research group behind this project wishes to thank the following associations
for their collaboration in the distribution of the study questionnaire: Asogaf–Asociación Granadina
de la Ataxia de Friedreich. Asociación de Enfermos Musculares de Granada. AGRADA Asociación
de Ataxias de Granada. Asociación española de afectados por Epilepsia Grave. Phelan Mcdermid.
22q13. Asociación Síndrome Shy Drager–Atrofia Multisistémica. Adisen–Asociación Nacional de Ad-
dison y Otras Enfermedades Endocrinas. ASENCO, Asociación de Enfermedades Neuromusculares
de Córdoba. Asociación 22 q Andalucía. Asociación Andaluza de Esclerosis Lateral Amiotrófica.
Asociación Andaluza de Fibrosis Quística. Asociación Andaluza de Hemofilia. Asociación Cordobesa
para la Investigación de Corea de Huntington. Asociación de Enfermedades Neuromusculares de
Andalucía. Asociación de Enfermos con Neurodegeneración por Acumulación Cerebral de Hierro.
Asociación de Familiares y Afectados Síndrome de Coffin-Lowry España. Asociación de Retinosis
Pigmentaria de Andalucía. Asociación del Síndrome de Prader Willi de Andalucía. Asociación
Española de Enfermos por Pseudoxantoma Elástico. Asociación Española de Familiares y Enfermos
de Wilson. Asociación Española para la Investigación y Ayuda al Síndrome de Wolfram. Asociación
Síndrome de Turner de Andalucía. Asociación Sindrome de Williams de Andalucía. Asociación
Valverdeña de la Enfermedad de Andrade. DEBRA Piel de Mariposa (Asociación de Epidermólisis
Bullosa de España). Federación Andaluza de Asociaciones de Ataxias. Asociación de Atrofia del
Nervio Óptico de Léber. Acción y Cura para Tay Sachs. ACTAYS. Asociación 11q España. Asociación
AMC–Artrogriposis Múltiple Congénita–España. Asociación de Afectados de Neurofibromatosis.
Asociación de Afectados Síndrome Landau –Kleffner. Asociación de Apoyo e Investigación del
Síndrome de 5p-. Asociación de Corea de Huntington Española. Asociación de Enfermedades Raras
de Alcalá de Henares. Asociación de Enfermos de Patología Mitocondrial. Asociacion de Familias
con Perthes. Asociación Española de Porfiria. Asociación Española del Síndrome de Beckwith–
Wiedemann. Asociación Española del Síndrome de Joubert. Asociación Huesos de Cristal de España.
Asociación Nacional Síndrome de Apert y otras Craneosinostosis Sindrómicas. Asociación de En-
fermedades Raras D’Genes. FEGEREC–Federación Gallega de enfermedades raras. Asociación
Chiari y Siringomielia del Principado de Asturias (CHySPA). Asociación Asturiana contra la Fibrosis
Quística (F.Q.). Asociación Ataxias de Extremadura. Asociación de Retinosis Pigmentaria Extremeña.
Asociación ELA Extremadura. Asociación Española de Cavernomas. Asociación Española de Lucha
contra las Hemoglobinopatias y Talasemias. Asociación Española de Stickler. Asociación Extremeña
contra la Fibrosis Quística. Asociación Extremeña de Enfermos de Huntington. Asociación La Vida
con Hernia Diafragmática Congénita. Asociación PrincesaRett. Asociación Síndrome X Frágil de
Extremadura. Alba, Asociación de Ayuda a Personas con Albinismo. Asociación “Síndrome de
Microdeleción 5q14.3–MEF2C”. Asociación ADIBI. Asociación de Discapacitados y Enfermedades
Int. J. Environ. Res. Public Health 2021, 18, 3234 9 of 10
Raras de IBI. Asociación Afectados CDKL5. Asociación Conquistando Escalones. Asociación de
Enfermedades Minoritarias de la Comunidad Valenciana. Asociación de Enfermedades Raras de
Benidorm y Comarca. Asociación de enfermedades raras y discapacidad Sense Barreres de Petrer.
Asociación de enfermos de FMF y síndromes autoinflamatorios de España. Asociación de Escleroder-
mia Castellón. Asociación de Fibrosis Quística de la Comunidad Valenciana. Asociación de lucha
contra la Distonía Mioclónica de Valencia. Asociación de Microsomia Hemifacial. Asociación de
Padres de Niños y Jóvenes con Enfermedades Reumáticas de la Comunidad Valenciana. Asociación
CADASIL España. Asociación Catalana de Espina Bífida e Hidrocefalia. Asociación Duchenne Som-
riures Valents. Asociación Española de Enfermos del Síndrome de Camurati–Engelmann. Asociación
Española del Síndrome de Cornelia de Lange. Asociación Microtia España. Asociación Síndrome
STXBP1. Associació Catalana de la Síndrome de Rett. Associació Catalana de Malaltia de Huntington.
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